tend to let the trades and share price do the talking. GLA
Is anyone here?
Must be the quietest board I have ever seen.
24 Nov '12
That's the sort of thing that happens to me. Was going to buy in here but went for aas instead. I worked in the pharma industry for years and lost my job due to the decrease in profitable small molecules. Larger biotech molecules have a bright future IMO. Pfizer acquired Wyeth for their biotech portfolio while contracting their small molecule business. Eli Lilly have an increasing biotech portfolio. Bearing in mind it takes about 10 years to get a drug to market and the biotech industry is still relatively young I thing this will do well in the longer term.
2 Nov '12
Just a blip ?
They say shares is all about timing, well I bough some BIOG shares about a month ago, having been very impressed with their long term share performance. Unfortunatley they have gone down 9% since I bough them. Just wondered if anybody more experienced than me has any views on why the current dip ? Thanks.
29 Jul '12
Outperformed NASDAQ Bio Index
BIOTECH GROWTH TRUST BEATS BENCHMARK Biotech Growth Trust outperformed its benchmark in the three months to the end of June. The trust's net asset value per share rose by 11.0% compared with a 7.6% rise in the NASDAQ Biotechnology Index measured in sterling terms. The company said the NAV performance was, in part, due to strong returns from portfolio holdings in Questcor Pharmaceuticals, following reports of strong sales of its multiple sclerosis treatment Acthar and also from Onyx Pharmaceuticals, following a positive vote from a US Food & Drug Administration Panel for the approval of its drug Carfilzomib for the treatment of advanced Myeloma. P.S. Here's a couple of links about SCLP, one of the hottest stocks at the moment: http://www.euroinvestor.com/community/discussionthread.aspx?threadid=256596 http://www.euroinvestor.com/community/discussionthread.aspx?threadid=253089
29 Jul '12
The Quarter’s Best Performer
Looking at individual investment portfolios, the Biotech Growth trust was the quarter’s best performer in terms of both net asset value (NAV) and share price. Over the three months, its NAV rose 19.1% while share price was up 11.4% on a total return basis. Source: http://www.fundweb.co.uk/investment-trusts/news/trusts-ahead-of-open-ended-peers-despite-q2-underperformance/1053944.article
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.